Introduction
Sorrento Therapeutics (SRNE) closed up 158% on news of a member of Sorrento’s proprietary G-MAB antibody library, STI-1499, demonstrating 100% in-vitro inhibition of Sars-CoV-2, the virus responsible for the global COVID-19 pandemic.
The results are preliminary and still require validation in the form of clinical trials and peer-review. But the science is compelling and the potential financial upside changes my previous recommendation of an across the board hold rating to a buy rating, for those non risk-averse investors seeking a possible home run from a clinical-stage bio-pharmaceutical.